Syncom Formulation (India)
Syncom Formulation (India) Performance
Day Range
- Low 8.45
- High 9.7
52 Week Range
- Low 4.6
- High 11.6
- Open Price8.55
- Previous Close8.4
- Volume16724057
Start SIP in Syncom Formulation (India)
Start SIPSyncom Formulation (India) Investment Rating
-
Master Rating:
-
Syncom Formulations India has an operating revenue of Rs. 232.69 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 12% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 4% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 114 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 59 | 61 | 57 | 54 | 51 | 58 |
Operating Expenses Qtr Cr | 53 | 55 | 51 | 50 | 48 | 56 |
Operating Profit Qtr Cr | 6 | 6 | 6 | 4 | 3 | 2 |
Depreciation Qtr Cr | 1 | 1 | 1 | 1 | 1 | 1 |
Interest Qtr Cr | 1 | 1 | 1 | 1 | 1 | 1 |
Tax Qtr Cr | 2 | 2 | 2 | 2 | 1 | 1 |
Net Profit Qtr Cr | 4 | 8 | 4 | 4 | 4 | 5 |
Syncom Formulation (India) Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹8.63
- 50 Day
- ₹8.41
- 100 Day
- ₹8.05
- 200 Day
- ₹7.88
- 20 Day
- ₹8.63
- 50 Day
- ₹8.5
- 100 Day
- ₹7.87
- 200 Day
- ₹7.5
Syncom Formulation (India) Resistance and Support
Resistance | |
---|---|
First Resistance | ₹9.91 |
Second Resistance | ₹10.4 |
Third Resistance | ₹11.11 |
RSI | 68.44 |
MFI | 53.29 |
MACD Single Line | 0.03 |
MACD | 0.06 |
Support | |
---|---|
First Resistance | ₹8.71 |
Second Resistance | ₹8 |
Third Resistance | ₹7.51 |
Syncom Formulation (India) Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 19,683,204 | 1,062,302,520 | 53.97 |
Week | 6,400,336 | 345,106,090 | 53.92 |
1 Month | 3,103,826 | 183,994,820 | 59.28 |
6 Month | 3,191,612 | 180,836,740 | 56.66 |
Syncom Formulation (India) Result Highlights
Syncom Formulation (India) Synopsis
NSE-Medical-Diversified
Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 224.64 Cr. and Equity Capital is Rs. 94.00 Cr. for the Year ended 31/03/2023. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.Market Cap | 888 |
Sales | 233 |
Shares in Float | 46.06 |
No of funds | 1 |
Yield | 1.01 |
Book Value | 3.47 |
U/D Vol ratio | 1 |
LTDebt / Equity | |
Alpha | 0.12 |
Beta | 0.46 |
Syncom Formulation (India)
Owner Name | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|
Promoters | 50.57% | 50.57% | 50.57% |
Mutual Funds | |||
Foreign Portfolio Investors | |||
Individual Investors | 45% | 44.85% | 45.02% |
Others | 4.43% | 4.58% | 4.41% |
Syncom Formulation (India) Management
Name | Designation |
---|---|
Mr. Kedarmal Shankarlal Bankda | Executive Chairman |
Mr. Vijay Shankarlal Bankda | Managing Director |
Mrs. Rinki Ankit Bankda | Whole Time Director |
Mr. Krishna Das Neema | Independent Director |
Mr. Praveen Jindal | Independent Director |
Mr. Vinod Kumar Kabra | Independent Director |
Mrs. Ruchi Jindal | Addnl. Independent Woman Director |
Syncom Formulation (India) Forecast
Price Estimates
Syncom Formulation (India) Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-08-14 | Quarterly Results | |
2023-05-29 | Audited Results | |
2023-02-13 | Quarterly Results | |
2022-11-14 | Quarterly Results | |
2022-08-13 | Quarterly Results & Final Dividend |
- Company Name
- CMP
- Chg(%)
- Bajaj Finance
- 7968
- 2.0
- Larsen & Toubro
- 3073
- 1.6
- Titan Company
- 3196
- 1.5
- Bajaj Finserv
- 1561
- 1.4
- Adani Ports
- 831
- 0.8
- Company Name
- CMP
- Chg(%)
- O N G C
- 185
- -3.8
- Eicher Motors
- 3351
- -2.8
- Hindalco Inds.
- 480
- -2.6
- Maruti Suzuki
- 10347
- -2.5
- Dr Reddys Labs
- 5462
- -2.2
Syncom Formulation (India) FAQs
What is Share Price of Syncom Formulation (India) ?
Syncom Formulation (India) share price is ₹9 As on 04 October, 2023 | 05:27
What is the Market Cap of Syncom Formulation (India) ?
The Market Cap of Syncom Formulation (India) is ₹885.5 Cr As on 04 October, 2023 | 05:27
What is the P/E ratio of Syncom Formulation (India) ?
The P/E ratio of Syncom Formulation (India) is 43 As on 04 October, 2023 | 05:27
What is the PB ratio of Syncom Formulation (India) ?
The PB ratio of Syncom Formulation (India) is 3.5 As on 04 October, 2023 | 05:27